Heart failure update 2010 and current ESC guidelines;Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien

Herz

Volumn 35, Issue 8, 2010, Pages 535-541

  Hoppe, U C ^a   Erdmann, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiac resynchronization; Evidence based; Guidelines; Heart failure; Pharmacotherapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; DIASTOLIC HEART FAILURE; EUROPE; EVIDENCE BASED PRACTICE; FUNCTIONAL STATUS; HEART FAILURE; HEART VENTRICLE FILLING; HUMAN; LOW DRUG DOSE; MORTALITY; PRACTICE GUIDELINE; PROGNOSIS; SYSTOLIC HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; DIASTOLE; DIURETICS; EUROPE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79151479002     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-010-3396-1     Document Type: Article

References (32)

1. Anker SD, Negassa A, Coats AJ, et al. (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361:1077-1083
2. Bardy GH, Lee KL, Mark DB, et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237
3. Bayram M, De Luca L, Massie MB, et al. (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96:47G-58G
4. Bhatia RS, Tu JV, Lee DS, et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260-269
5. Bradley DJ, Bradley EA, Baughman KL, et al. (2003) Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 289:730-740
6. Bristow MR, Saxon LA, Boehmer J, et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150
7. Brixius K, Middeke M, Lichtenthal A, et al. (2007) Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34:327-331
8. CIBIS-II, Investigators, and, et al. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13
9. Cleland JG, Daubert JC, Erdmann E, et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549
10. Corra U, Pistono M, Mezzani A, et al. (2006) Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence. Circulation 113:44-50
11. Dickstein K, Cohen-Solal A, Filippatos G, et al. (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 29:2388-2442
12. Flather MD, Shibata MC, Coats AJ, et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225
13. Fuster V, Ryden LE, Cannom DS, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. Eur Heart J 27:1979-2030
14. Hjalmarson A, Goldstein S, Fagerberg B, et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA 283:1295-1302
15. Hoppe UC, Böhm M, Dietz R, et al. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 94:488-509
16. Kjekshus J, Apetrei E, Barrios V, et al. (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261
17. Krum H, Roecker EB, Mohacsi P, et al. (2003) Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289:712-718
18. Lainscak M, Anker SD (2009) Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz 34:141-147
19. Lemke B, Nowak B, Pfeiffer D (2005) Leitlinien zur Herzschrittmachertherapie. Z Kardiol 94:704-720
20. Mebazaa A, Nieminen MS, Packer M, et al. (2007) Levosimendan vs Dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883-1891
21. Moss AJ, Zareba W, Hall WJ, et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883
22. Pitt B, Zannad F, Remme W, et al. for the Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717
23. Pitt B, Remme W, Zannad F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
24. Remme WJ, Swedberg K (2002) Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 4:11-22
25. Sipahi I, Debanne SM, Rowland DY, et al. (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11:627-636
26. SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302
27. Swedberg K, Cleland J, Dargie H, et al. (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115-1140
28. Swedberg K, Komajda M, Bohm M, et al. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875-885
29. Tavazzi L, Maggioni AP, Marchioli R, et al. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231-1239
30. Tschope C, Westermann D (2009) Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 34:89-96
31. Vardas PE, Auricchio A, Blanc JJ, et al. (2007) Guidelines for cardiac pacing and cardiac resynchronization therapy. Eur Heart J 28:2256-2295
32. Yusuf S, Teo KK, Pogue J, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559